Acute Myeloid Leukemia Clinical Trial

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Summary

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.

View Full Description

Full Description

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory higher-risk myelodysplastic syndrome.

The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009 in relapsed and refractory AML. The expansion part, (Part B), will further evaluate the safety and efficacy of CC-90009 administered at or below the maximum tolerated dose (MTD) in selected expansion cohorts of one or more dosing regimens in order to determine the recommended Phase 2 dose (RP2D) for subjects with relapsed or refractory AML and relapsed or refractory higher-risk myelodysplastic syndrome.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Consent Document).
Subject must understand and voluntarily sign an ICD prior to any study-related assessments/procedures being conducted.

Relapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or refractory (R/R) higher-risk MDS (Myelodysplastic Syndrome) (HR-MDS) (Part B only) as defined by World Health Organization criteria who are not suitable for other established therapies.

In Part A, R/R AML

In Part B, R/R AML including

Relapsed after allogeneic HSCT or
In second or later relapse or
Refractory to initial induction or re-induction treatment or
Refractory or relapse after HMA treatment (HMA failure defined as primary progression or lack of clinical benefit after a minimum of 6 cycles or unable to tolerate HMA due to toxicity) or
Refractory within 1 year of initial treatment (excluding those with favorable risk based on cytogenetics)

In Part B, R/R HR-MDS (Revised International Prognostic Scoring System score (IPSS-R) > 3.5 points, IPSS-R calculated during screening period):

IPSS-R intermediate risk (in combination with more than 10% bone marrow blasts or poor or very poor IPSS-R cytogenetic risk) or
IPSS-R high or
IPSS-R very high risk
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.
At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning.

Subjects must have the following screening laboratory values:

Corrected serum Ca or free (ionized) serum Ca within normal limits (WNL).

o Corrected Ca (mg/dL) = Total Ca (mg/dL) - 0.8 (albumin [g/dL] - 4)

Total White Blood Cell count (WBC) < 25 x 10^9/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.
Potassium and magnesium within normal limits or correctable with supplements.
Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) or alanine aminotransferase/serum glutamate pyruvic transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN).
Uric acid ≤ 7.5 mg/dL (446 μmol/L). Prior and/or concurrent treatment with hypouricemic agents (eg, allopurinol, rasburicase) are allowed.
Selected electrolytes within normal limits or correctable with supplements.
Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).
Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.
International normalized ratio (INR) < 1.5 x ULN and Partial thromboplastin time (PTT) < 1.5 x ULN.

Exclusion Criteria:

Subjects with acute promyelocytic leukemia (APL)
Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is clinical suspicion of CNS involvement by leukemia during screening.
Patients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects).
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90009.
Subjects on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD).
Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90009, whichever is shorter. Hydroxyurea is allowed to control peripheral leukemia blasts.
Leukapheresis ≤ 2 weeks prior to starting CC-90009.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

162

Study ID:

NCT02848001

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 21 Locations for this study

See Locations Near You

Yale Cancer Center
New Haven Connecticut, 06510, United States
Yale Cancer Center
New Haven Connecticut, 06510, United States More Info
Amer Zeidan, Site 105
Contact
203-737-7078
Northwestern Memorial
Chicago Illinois, 60611, United States
Northwestern Memorial
Chicago Illinois, 60611, United States More Info
Jessica Altman, Site 102
Contact
312-503-1794
Dana Farber Cancer Institute
Boston Massachusetts, 02115, United States
Washington University Siteman Cancer Center
Saint Louis Missouri, 63110, United States
Washington University Siteman Cancer Center
Saint Louis Missouri, 63110, United States More Info
Geoffrey Uy, Site 101
Contact
314-454-8304
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Princess Margaret Hospital University Health Network
Toronto Ontario, M5G 2, Canada
Local Institution - 505
Lillie Cedex , 59037, France More Info
Site 505
Contact
Institut Paoli Calmettes
Marseille Cedex 9 , 13273, France
Local Institution - 504
Pessac Cedex , 33604, France More Info
Site 504
Contact
Hopital Lyon Sud
Pierre Benite , 69310, France
Hopital Lyon Sud
Pierre Benite , 69310, France More Info
Mael Heiblig, Site 503
Contact
Institut Claudius Regaud, IUCT-Oncopole
Toulouse , 31059, France
Haukeland University Hospital
Bergen , N-505, Norway
Local Institution - 701
Oslo , N-002, Norway More Info
Site 701
Contact
Oslo University Hospital, Rikshospitalet HF
Oslo , N-002, Norway
Hospital Germans Trias I Pujol
Badalona , 8916, Spain
Local Institution - 603
Badalona , 8916, Spain More Info
Site 603
Contact
H Clinic I Provincial
Barcelona , 08036, Spain
Local Institution - 602
Barcelona , 08036, Spain More Info
Site 602
Contact
Local Institution - 604
Madrid , 28033, Spain More Info
Site 604
Contact
MD Anderson Cancer Center - Madrid
Madrid , 28033, Spain
Clinica Universidad de Navarra
Pamplona , 31008, Spain
Local Institution - 605
Pamplona , 31008, Spain More Info
Site 605
Contact
Hospital Clinico Universitario de Salamanca
Salamanca , 37007, Spain
Local Institution - 601
Salamanca , 37007, Spain More Info
Site 601
Contact
Hosptial La Fe
Valencia , 46009, Spain
Clatterbridge Cancer Centre - Liverpool
Liverpool , L9 7B, United Kingdom
Local Institution - 301
Oxford , 0X3 7, United Kingdom More Info
Site 301
Contact
The Churchill Hospital
Oxford , 0X3 7, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

162

Study ID:

NCT02848001

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.